DexCom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring ("CGM"), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. U.S. revenue is expected to be approximately $373 million, representing growth of 33% over the fourth quarter of 2018. International revenue is expected to be approximately $84 million, an increase of 47% over the fourth quarter of 2018.
For fiscal 2019, total preliminary, unaudited revenue is expected to be approximately $1.470 billion, an increase of more than 42% over 2018.
"2019 was another amazing year for Dexcom, demonstrating the growing awareness of real-time CGM for managing diabetes and customer excitement for our G6 platform. This was the second consecutive year of greater than 40% growth, far exceeding our own expectations and a strong accomplishment for a company of our size," said Kevin Sayer, Dexcom's Chairman, President and CEO. "We are hitting the ground running in 2020 and believe we are well positioned to continue our growth momentum."
For 2020, Dexcom currently anticipates total revenue of approximately $1.725 billion to $1.775 billion, representing expected growth of approximately 17% to 21% over 2019. This growth outlook is driven by strong growth in sensor volumes, continued international expansion, shifting channel mix and overall market dynamics.
Dexcom will provide further details related to its 2020 financial expectations on the fourth quarter earnings call.